NCT01010893 - Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine | Biotech Hunter

Enrollment

355

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

September 30, 2009

Study Completion Date

February 28, 2010

Conditions

Influenza

Interventions

BIOLOGICAL

Vaccination with Fluval P and Fluval AB influenza vaccines

Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose) AND with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 3x15 μg HA/ in both age groups, single dose).

BIOLOGICAL

Vaccination with Fluval P monovalent influenza vaccine

Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant

Trial Locations (2)

H-2085

District Doctor's Office, Pilisvörösvár

H-8200

Fourmed Kft. Gyogyhaz, Veszprém